Clinical Trials Logo

ARDS clinical trials

View clinical trials related to ARDS.

Filter by:

NCT ID: NCT05493839 Active, not recruiting - Ards Clinical Trials

A Reverification of the Berlin Definition Plateau Criteria in Golmud

Start date: June 20, 2022
Phase:
Study type: Observational

This study is a single-center retrospective study. According to the Berlin diagnostic standard, ARDS patients admitted to the Department of severe Medicine, Golmud People's Hospital from January 2015 to june 2022 were divided into three groups: mild (142mmHg < PaO2/ FiO2 ≤ 213 mmHg), moderate (71mmHg < PaO2/ FiO2 ≤ 142mmHg) and severe (PaO2/ FiO2 ≤ 71 mmHg). The ICU mortality, 28-day mortality, non-ventilator time in ICU, ICU hospitalization time observed respectively.

NCT ID: NCT05473130 Suspended - Heart Failure Clinical Trials

Breethe Abiomed Recovery regisTry (BART)

BART
Start date: March 31, 2021
Phase:
Study type: Observational

The BART Registry intended to utilize observational data of the Abiomed Breethe OXY-1 System™ in real-world settings to drive best practice usage patterns, serve as a tool to measure and improve the quality of patient care and as a resource to inform us on the design of future studies.

NCT ID: NCT05464680 Recruiting - ARDS Clinical Trials

Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia

ATB-COVID
Start date: November 24, 2022
Phase: N/A
Study type: Interventional

Patients on mechanical ventilation (MV) following SARS-CoV-2 pneumonia frequently develop ventilator-associated pneumonia (VAP). The incidence of MVAP during SARS-CoV-2 infections ranges from 50 to nearly 90%. In addition, up to 80% of recurrences of VAP (a new episode, most often attributable to the same bacteria) have been described, reflecting the failure of the initial antibiotic therapy. This incidence is much higher than that described for other etiologies of acute respiratory distress syndrome (ARDS). The investigators hypothesize that during VAP, there is an alteration of the diffusion of intravenous antibiotics in the lung parenchyma in COVID-19 patients in relation to several factors characteristic of SARS-CoV-2 infection. This altered diffusion may explain the high number of recurrences of MVAP compared to non-COVID-19 patients.

NCT ID: NCT05453214 Completed - COVID-19 Clinical Trials

Mineralocorticoid Use in COVID-19 Patients

Start date: December 4, 2021
Phase: Phase 3
Study type: Interventional

There is a considerable variability in aldosterone levels between individuals, and this may explain the wide variability in disease severity among those infected so we designed a pilot study to test for the safety and efficacy of fludrocortisone addition to standard of care in hospitalised COVID-19 patients.

NCT ID: NCT05414110 Recruiting - ARDS Clinical Trials

Effect of Airway Pressure Release Ventilation on Right Ventricular Function Assessed by Transthoracic Echocardiography

Start date: April 3, 2022
Phase:
Study type: Observational

Effects of APRV on right ventricular function in patients with acute respiratory distress syndrome by transthoracic echocardiography

NCT ID: NCT05408442 Recruiting - Clinical trials for Mechanical Ventilation

Role of Pulmonary Perfusion on Tolerance to Supine Position in Patients With ARDS

Start date: July 1, 2021
Phase:
Study type: Observational [Patient Registry]

The relationship between the presence or absence of endothelial dysfunction and changes in pulmonary perfusion will be evaluated, to then determine if there is any association between changes in the V / Q ratio and tolerance to the supine position after a prone cycle in patients with acute respiratory distress syndrome on mechanical ventilation.

NCT ID: NCT05406427 Recruiting - ARDS Clinical Trials

Monitorings the Physiological Mechanism of Airway Pressure Release Ventilation in ARDS Patients by EIT

Start date: March 1, 2022
Phase:
Study type: Observational

Effects of airway pressure release ventilation on pulmonary ventilation, shunt and perfusion in patients with ARDS

NCT ID: NCT05384379 Terminated - ARDS Clinical Trials

Efficacy and Safety Evaluation of BZ371B in ARDS Patients

Start date: November 23, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability and efficacy of BZ371B in intubated patients with severe Acute Respiratory Distress Syndrome.

NCT ID: NCT05371314 Active, not recruiting - ARDS Clinical Trials

Artificial Intelligence in Categorizing the Severity of Oxygenation by Incorporating the PEEP Into the Definition of ARDS in Ventilated Patients

P/FP ratio
Start date: December 1, 2021
Phase:
Study type: Observational

Artificial Intelligence in categorizing the severity of Oxygen in ventilated patients to predict initiation of treatment measures to improve mortality - P/FP ratio

NCT ID: NCT05354141 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Start date: July 1, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).